Antisense strategies for the treatment of neurological disease

Bibliography

• BENSIMON G, LACOMBLEZ L: A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/riluzole study group. N Engl. J. Med. (1994) 330:585–591.
   PubMed Web of Science ®Google Scholar
• MILLER RG, MITCHELL JD, MOORE DH: Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev. (2000) CD001447.
   Google Scholar
• PARKINSON STUDY GROUP: A multicenter randomizedcontrolled trial of remacemide hydrochloride as monotherapy for PD. Neurology (2000) 54:1583–1588.
   PubMed Web of Science ®Google Scholar
• KIEBURTZ K: An tiglutam ate therapies in Huntington's disease. J. Neural Transm. (1999) 55 (Suppl.) :97–102.
   Google Scholar
• CHEN M, ONA VO, LI M et al.: Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Hunting-ton's disease. Nat. Merl. (2000) 6:797–801.
   PubMedGoogle Scholar
• TATTON WG, WADIA JS, JU WY, CHALMERS-REDMAN RM,TATTON NA: (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. Neural Transm. (1996) 48 (Suppl.) :45–59.
   Google Scholar
• KRAGTEN E, LALANDE I, ZIMMERMAN K et al.:Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl. J. Biol. Chem. (1998) 273:5821–5828.
   PubMedGoogle Scholar
• SEIDMAN S, ECKSTEIN F, GRIFMAN M, SOREQ H: Antisense technologies have a future fighting neurodegenerative diseases. Antisense Nucl. Acid Drug Dev. (1999) 9:333–340.
   PubMedGoogle Scholar
• ISHITANI R, CHUANG DM: Glyceraldehyde-3-phosphate dehydrogenase antisense oligodeoxynucleotides protect against cytosine arabinonucleoside-induced apoptosis in cultured cerebellar neurons. Proc. NatL Acad. ScL USA (1996) 93:9937–9941.
   PubMedGoogle Scholar
• ISENMANN S, ENGEL S, GILLARDON F, BAHR M: Bax antisense oligonucleotides reduce axotomy-induced retinal ganglion cell death in vivo by reduction of Bax protein expression. Cell Death Differ. (1999) 6:673–682.
   PubMedGoogle Scholar
• GUO Q, FU W, XIE J et al.: Par-4 is a mediator ofneuronal degeneration associated with the pathogenesis of Alzheimer's disease. Nat. Merl. (1998) 4:957–962.
   PubMed Web of Science ®Google Scholar
• DUAN W, ZHANG Z, GASH DM, MATTSON MP: Participa-tion of prostate apoptosis response-4 in degeneration of dopaminergic neurons in models of Parkinson's disease. Ann. Neurol. (1999) 46:587–597.
   PubMed Web of Science ®Google Scholar
• PEDERSEN WA, LUO H, KRUMAN I, KASARSKIS E, MATTSON MP: The prostate apoptosis response-4 protein participates in motor neuron degeneration in amyotrophic lateral sclerosis. FASEB J. (2000) 14:913–924.
   PubMed Web of Science ®Google Scholar
• HUNOT S, BRUGG B, RICARD D et al.: Nuclear transloca-tion of NF-KB is increased in dopaminergic neurons of patients with Parkinson's disease. Proc. Natl. Acad. Sci. USA (1997) 94:7531–7536.
   PubMed Web of Science ®Google Scholar
• BALES KR, DU Y, DODEL RC, YAN GM, HAMILTON-BYRD E, PAUL SM: The NF-KB/Rel family of proteins mediates A13-induced neurotoxicity and glial activation. Brain Res. Mol. Brain Res. (1998) 57:63–72.
   PubMedGoogle Scholar
• LARNER AJ: Neuronal apoptosis as a therapeutic target in neurodegenerative disease. Exp. Opin. Ther. Patents (2000) 10:1493–1518.
   Web of Science ®Google Scholar
• WANG J, SHOU J, CHEN X: Dickkopf-1, an inhibitor of the Wnt signaling pathway, is induced by p53. Oncogene (2000) 19: 1843-1848.
   Google Scholar
• KAWASAKI H, SPRINGETT GM, TOKI SA et al: A Rap guanine nucleotide exchange factor enriched highly in the basal ganglia. Proc. Natl. Acad. Sci. USA (1998) 95:13278–13283.
   PubMed Web of Science ®Google Scholar
• MOCHIZUKI N, OHBA Y, KOBAYASHI S, OTSUKA N, GRAYBIEL AM, TANAKA S, MATSUDA M: Crk activation of JNK via C3G and R-Ras. J. Biol. Chem. (2000) 275:12667–12671.
   PubMedGoogle Scholar
• CUMMINGS JL: Current perspectives in Alzheimer's disease. Neurology (1998) 51 (Supp1.1):S1.
   Google Scholar
• DUNKIN JJ, ANDERSON-HANLEY C: Dementia caregiver burden. A review of the literature and guidelines for assessment and intervention. Neurology (1998) 51 (Supp1.1):S53–S60.
   Google Scholar
• FOSTER RH, PLOSKER GL: Donepezil. Pharma-coeconomic implications of therapy. Pharma-coeconomics (1999) 16:99–114.
   Google Scholar
• HAUBER AB, GNANASAKTHY A, SNYDER EH, BALA MV, RICHTER A, MAUSKOPF JA: Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine. Pharmacoeconomics (2000) 17:351–360.
   PubMed Web of Science ®Google Scholar
• BIRKS J, IAKOVIDOU V, TSOLAKI M: Rivastigmine for Alzheimer's disease. Cochrane Database Syst. Rev. (2000) CD001191.
   Google Scholar
• BIRKS JS, MELZER D, BEPPU H: Donepezil for mild and moderate Alzheimer's disease (Cochrane Review). Cochrane Database Syst. Rev. (2000) CD001190.
   Google Scholar
• ST.GEORGE-HYSLOP PH: Molecular genetics of Alzheimer's disease. Semin. Neurol (1999) 19:371–383.
   Google Scholar
• SCHENK D, BARBOUR R, DUNN W et al.: Immunizationwith amyloid-13 attenuates Alzheimer- disease-like pathology in the PDAPP mouse. Nature (1999) 400 :173–177.
   PubMed Web of Science ®Google Scholar
• BARD F, CANNON C, BARBOUR R et al.: Peripherally administered antibodies against amyloid 13-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. (2000) 6:916–919.
   PubMed Web of Science ®Google Scholar
• JANUS C, PEARSON J, MCLAURIN J et al.: A13 peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2000) 408:979–982.
   PubMed Web of Science ®Google Scholar
• MORGAN D, DIAMOND DM, GOTTSCHALL PE et al.: A13 peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2000) 408:982–985.
   PubMed Web of Science ®Google Scholar
• MCGEER PL, SCHULZER M, MCGEER EG: Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemi-ologic studies. Neurology (1996) 47:425–432.
   PubMed Web of Science ®Google Scholar
• SANO M, ERNESTO C, THOMAS RG et al.: A controlled trial of selegiline, a-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's disease cooperative study. N Engl. J. Med. (1997) 336:1216–1222.
   Google Scholar
• SOREQ H, SEIDMAN S: Anti-sense approach to anticho-linesterase therapeutics. Isr. Med. Assoc. J. (2001) 2 (Suppl.):81–85.
   Google Scholar
• CHANG KA, KIM SH, SAKAKI Y, KIM HS, PARK CW, SUH YH: Inhibition of the NGF and IL-113-induced expres-sion of Alzheimer's amyloid precursor protein by antisense oligonucleotides. J. Mol. Neurosci. (1999) 12:69–74.
   PubMedGoogle Scholar
• VASSAR R, BENNETT BD, BABU-KHAN S et al.: 13-Secr etase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE Science (1999) 286:735–741.
   Google Scholar
• DODEL RC, DU Y, BALES KR etal.: a2 Macroglobulin and the risk of Alzheimer's disease. Neurology (2000) 5 4:438–442.
   Google Scholar
• HYMAN BT, STRICKLAND D, REBECK GW: Role of the low-density lipoprotein receptor-related protein in beta-amyloid metabolism and Alzheimer's disease. Arch. Neurol. (2000) 57:646–650.
   PubMed Web of Science ®Google Scholar
• DU Y, BALES KR, DODEL RC et al.: a2-Macroglobulin attenuates 3-amyloid peptide 1-40 fibril formation and associated neurotoxicity of cultured fetal rat cortical neurons. J Neurochem. (1998) 70:1182–1188.
   PubMed Web of Science ®Google Scholar
• HUGHES SR, KHORKOVA 0, GOYAL S et al.: a2-Macroglobulin associates with 13-amyloid peptide and prevent fibril formation. Proc. Nati Acad. Sci. USA (1998) 95:3275–3280.
   Google Scholar
• FABRIZI C, BUSINARO R, LAURO GM, STARACE G, FUMAGALLI L: Activated a2-Macroglobulin increases 13-amyloid (25-35)-induced toxicity in LAN5 human neuroblastoma cells. Exp. Neurol. (1999) 155:252–259.
   PubMedGoogle Scholar
• QIU Z, STRICKLAND DK, HYMAN BT, REBECK GW: a2-Macroglobulin enhances the clearance of endoge-nous soluble 13-amyloid peptide via low-density lipoprotein receptor-related protein in cortical neurons. J Neurochem. (1999) 73:1393-1398. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Ther. Patents (2001) 11(4)
   Google Scholar
• MONJI A, YOSHIDA I, TASHIRO K, HAYASHI Y, MATSUDA K, TASHIRO N: Inhibition of A13 fibril formation and A13-induced cytotoxicity by senile plaque-associated proteins. NeuroscL Lett. (2000) 278:81–84.
   PubMedGoogle Scholar
• Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease. Exp. Opin. Ther. Patents (1999) 9 (2):201–204.
   Google Scholar
• BEAL MF: Energetics in the pathogenesis of neurode-generative diseases. TINS (2000) 23:298–304.
   PubMed Web of Science ®Google Scholar
• BETARBET R, SHERE TB, MACKENZIE G, GARCIA-OSUNA M, PANOV AV, GREENAMYRE JT: Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. NeuroscL (2000) 3:1301–1306.
   PubMed Web of Science ®Google Scholar
• POLYMEROPOULOS MH, LAVEDAN C, LEROY E et al: Mutation in the a-synuclein gene identified in families with Parkinson's disease. Science (1997) 276:2045–2047.
   PubMed Web of Science ®Google Scholar
• GOLDBERG MS, LANSBURY PT, JR.: Is there a cause-and-effect relationship between a-synuclein fibrillization and Parkinson's disease? Nat. Cell. Biol. (2000) 2:E115–E119
   Google Scholar
• SHIMURA H, HATTORI N, KUBO SI et al: Familial Parkin-son's disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. (2000) 25:302–305.
   PubMed Web of Science ®Google Scholar
• KANDA S, BISHOP JF, EGLITIS MA, YANG Y, MOURADIAN MM: Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation. Neuroscience (2000) 97:279–284.
   PubMed Web of Science ®Google Scholar
• KO LW, MEHTA ND, FARRER M et al.: Sensitization ofneuronal cells to oxidative stress with mutated human a-synuclein. j Neurochem. (2000) 75:2546–2554.
   PubMedGoogle Scholar
• MCGEER PL, ITAGAKI S, BOYES BE, MCGEER EG: Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease of brains. Neurology (1988) 38:1285–1291.
   PubMed Web of Science ®Google Scholar
• DOUCET J-P, NAKABEPPU Y, BEDARD PJ et al.: Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of FosB-like protein (s) in both the rodent and primate striatum. Eur. J. NeuroscL (1997) 8:365–381.
   Google Scholar
• BORDET R, RIDRAY S, CARBONI S, DIAZ J, SOKOLOFF P,SCHVVARTZ J-C: Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitiza-tion to levodopa. Proc. Natl. Acad. ScL USA (1997) 94:3363–3367.
   PubMed Web of Science ®Google Scholar
• ENGBER TM, SUSEL Z, KUO S, GERFEN CR, CHASE TN: lzvodopa replacement therapy alters enzyme activi-ties in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res. (1991) 5 5 2:113–118.
   Google Scholar
• VAN KAMPEN JM, STOESSL AJ: Effects of oligonucleotide antisense to dopamine DiAreceptor mRNAin a rodent model of levodopa-induced dyskinesia. Neuroscience (2000) 98:61–67.
   PubMed Web of Science ®Google Scholar
• VAN KAMPEN JM, STOESSL AJ: Dopamine D3 receptor antisense attenuates levodop a-induced behavioural sensitization in rats. Soc. NeuroscL Abstr. (1999) 25:336 (Abstract).
   Google Scholar
• CROCKER SJ, MORELLI M, WIGLE N, NAKABEPPU Y, ROBERTSON GS: Di-receptor-related priming is attenu-ated by antisense-mediated 'knockdown' of fosB expression. Brain Res. Mol. Brain Res. (1998) 53:69–77.
   PubMedGoogle Scholar
• ANDERSSON M, HILBERTSON A, CENCI MA: Striatal fosBexpression is causally linked with 1-DOPA-induced abnormal involuntary movements and the associated upreg-ulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol Dis. (1999) 6:461–474.
   PubMed Web of Science ®Google Scholar
• SIMANTOV R, BLINDER E, RATOVITSKI T, TAUBER M, GABBAY M, PORAT S: Dopamine-induced apoptosis in human neuronal cells: inhibition by nucleic acids antisense to the dopamine transporter. Neuroscience (1996) 74:39–50.
   PubMed Web of Science ®Google Scholar
• GAINETDINOV RR, FUMAGALLI L, JONES SR, CARON MG:Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem. (1997) 69:1322–1325.
   PubMed Web of Science ®Google Scholar
• BEZARD E, GROSS CE, FOURNIER MC, DOVERO S, BLOCH B, JABER M: Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp. Neurol (2000) 155:268–273.
   Google Scholar
• VAN KAMPEN JM, MCGEER EG, STOESSL AJ: Dopamine transporter function assessed by antisense knockdown in the rat: protection from dopamine toxicity. Synapse (2000) 3 7 :171–178.
   Google Scholar
• NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERSAND STROKE RT-PA STROKE STUDY GROUP: Tissue plasminogen activator for acute ischemic stroke. N Engl. J. Med. (1995) 333:1581–1587.
   PubMedGoogle Scholar
• BROTT T, BOGOUSSLAVSKY J: Treatment of acuteischemic stroke. N Engl. J. Med. (2000) 343:710–722.
   PubMed Web of Science ®Google Scholar
• WARDLAW JM, DEL ZOPPO G, YAMAGUCHI T: Thrombolysis for acute ischaemic stroke. Cochrane Database Syst. Rev. (2000) CD000213.
   Google Scholar
• DE KEYSER J, SULTER G, LUITEN PG: Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? TINS (1999) 22:535–540.
   PubMed Web of Science ®Google Scholar
• LUTSEP HL, CLARK WM: Neuroprotection in acute ischaemic stroke. Current status and future potential. Drugs R D (1999) 1:3–8.
   Google Scholar
• DEGRABA TJ, PETTIGREW LC: Why do neuroprotective drugs work in animals but not humans? Neurol. Clin. (2000) 18:475–493.
   Google Scholar
• WAHLESTEDT C, GOLANOV E, YAMAMOTO S, YEE F, ERICSON H, Y00 H, INTURRISI CE, REIS DJ: Antisense oligodeoxynucleotides to NNIDA-R1 receptor channel protect cortical neurons from ex citotoxicity and reduce focal ischaemic infarctions. Nature (1993) 363:260–263.
   PubMed Web of Science ®Google Scholar
• TAMATANI M, OGAWA S, NIITSU Y, TOHYAMA M: Involvement of Bc1-2 family and casp ase-3 -like © Ashley Publications Ltd. All rights reserved.Exp. Opin. Ther. Patents (2001) 11(4) protease in NO-mediated neuronal apoptosis. J. Neurochem. (1998) 71:1588–1596.
   Google Scholar
• MATTHEWS PM, DE STEFANO N, NARAYANAN S et al: Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Semin. Neurol (1998) 18:327–336.
   PubMed Web of Science ®Google Scholar
• SILBER E, SHARIEF MK: Axonal degeneration in the pathogenesis of multiple sclerosis. J Neurol. Sci. (1999) 1 70:11–18.
   Google Scholar
• IFNB MULTIPLE SCLEROSIS STUDY GROUP.: Interferon 13-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, random-ized, double-blind, placebo-controlled trial. Neurology (1993) 43 :655–661.
   Google Scholar
• JACOBS LD, COOKFAIR DL, RUDICK RA et al.: Intramus-cular interferon 13-1 a for disease progression in relapsing multiple sclerosis. Ann. Neurol (1996) 39:285–294.
   PubMed Web of Science ®Google Scholar
• PREVENTION OF RELAPSES AND DISABILITY BY INTERFERON BETA-1A SUBCUTANEOUSLY IN MULTIPLE SCLEROSIS (PRIMS) STUDY GROUP: Randomised double-blind placebo-controlled study of interferon 13-la in relapsing/remitting multiple sclerosis. Lancet (1998) 352:1498–1504.
   PubMedGoogle Scholar
• LA MANTIA L, MILANESE C, D'AMICO R: Meta-analysis of clinical trials with copolymer 1 in multiple sclerosis. Eur. Neurol (2000) 43:189–193.
   PubMedGoogle Scholar
• NOSEWORTHY JH, LUCCHINETTI C, RODRIGUEZ M, WEINSHENKER BG: Multiple sclerosis. N Engl. J. Med. (2000) 343:938–952.
   PubMed Web of Science ®Google Scholar
• WOJCIK WJ, SWOVELAND P, ZHANG X, VANGURI P: Chronic intrathecal infusion of phosphorothioate or phosphodiester antisense oligonucleotides against cytokine responsive gene-2/IP-10 in experimental allergic encephalomyelitis of Lewis rat. J Pharmacol. Exp. Therap. (1996) 278:404–410.
   PubMedGoogle Scholar
• DING M, ZHANG M, WONG JL, ROGERS NE, IGNARRO LJ, VOSKUHL RR: Antisense knockdown of inducible nitric oxide synthase inhibits induction of experimental autoimmune encephalomyelitis in SJL/J mice. J. Immunol. (1998) 160 :2560–2564.
   PubMed Web of Science ®Google Scholar
• SUN FY, FADEN Al: Pretreatment with antisense oligodeoxynucleotides directed against the NMDA-R1 receptor enhances survival and behavioral recovery following traumatic brain injury in rats. Brain Res. (1995) 693:163–168.
   PubMedGoogle Scholar
• GHIRNIKAR RS, LEE YL, LIK JD, ENG LF: Chemokine inhibition in rat stab wound brain injury using antisense oligodeoxynucleotides. Neurosci. Lett. (1998) 247:21–24.
   PubMed Web of Science ®Google Scholar
• CAMPBELL JW, POLLACK IF: Growth factors in gliomas: antisense and dominant negative mutant strategies. J Neurooncol. (1997) 35:275–285.
   PubMedGoogle Scholar
• ENGELHARD HH: Antisense oligodeoxynucleotide technology: potential use for the treatment of malignant brain tumors. Cancer Control (1998) 5:163–170.
   PubMedGoogle Scholar
• ENGELHARD HH, EGLI M, ROZENTAL JM: Use of antisense vectors and oligodeoxynucleotides in neuro-oncology. Pediatr. Neurosurg. (1998) 28:279–285.
   PubMedGoogle Scholar
• CHO-CHUNG YS: Antisense and therapeutic oligonu-cleotides: toward a gene-targeting cancer clinic. Exp. Opin. Ther. Patents (2000) 10:1711–1724.
   Web of Science ®Google Scholar
• JULIEN T, FRANKEL B, LONGO S et al.: Antisense-mediated inhibition of the bc1-2 gene induces apoptosis in human malignant glioma. Surg. Neurol (2000) 53:360–368.
   PubMedGoogle Scholar
• SHEN L, DEAN NM, GLAZER RI: Induction of p53-dependent, insulin-like growth factor-binding protein-3-mediated apoptosis in glioblastoma multiforme cells by a protein kinase Ca antisense oligonucleotide. Mol. Pharmacol (1999) 55:396–402.
   PubMedGoogle Scholar
• BROADDUS WC, CHEN ZJ, PRABHU SS et al: Antiprolif-erative effect of c-myc antisense phosphorothioate oligodeoxynucleotides in malignant glioma cells. Neurosurgery (1997) 41:908–915.
   PubMedGoogle Scholar
• REDEKOP GJ, NAUS CC: Transfection with bFGF sense and antisense cDNA resulting in modification of malignant glioma growth. J. Neurosurg. (1995) 82:83–90.
   PubMedGoogle Scholar
• YAMADA SM, YAMAGUCHI F, BROWN R, BERGER MS, MORRISON RS: Suppression of glioblastoma cell growth following antisense oligonucleotide-mediated inhibition of fibroblast growth factor receptor expres-sion. Glia (1999) 28 :66–76.
   PubMed Web of Science ®Google Scholar
• TANG P, JASSER SA, SUNG JC, SHI Y, STECK PA, YUNGWK: Transforming growth factor-a antisense vectors can inhibit glioma cell growth. J Neurooncol (1999) 43:127–135.
   PubMedGoogle Scholar
• FAKHRAI H, DORIGO 0, SHAWLER DL et al.: Eradication of established intracranial rat gliomas by transforming growth factor 13 antisense gene therapy. Proc. Natl. Acad. Sci. USA (1996) 93:2909–2914.
   Google Scholar
• LIAU LM, FAKHRAI H, BLACK KL: Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF-I3 antisense gene. Neurol. Res. (1998) 20:742–747.
   PubMed Web of Science ®Google Scholar
• KONDO S, KONDO Y, LI G, SILVERMAN RH, COWELL JK:Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene (1998) 16:3323–3330.
   PubMed Web of Science ®Google Scholar
• MUKAI S, KONDO Y, KOGA S, KOMATA T, BARNA BP,KONDO S: 2-5A antisense telomerase RNA therapy for intracranial malign ant gliomas. Cancer Res. (2000) 60:4461–4467.
   PubMed Web of Science ®Google Scholar
• YAMAOKA K, MISHIMA K, NAGASHIMA Y, ASAI A, SANAIY, KIRINO T: Expression of galectin-1 mRNA correlates with the malignant potential of human gliomas and expression of antisense galectin-1 inhibits the growth of 9 glioma cells. J. Neurosci. Res. (2000) 59:722–730.
   PubMed Web of Science ®Google Scholar
• MOHAN PM, CHINTALA SK, MOHANAM S et al.: Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth. Cancer Res. (1999) 59:3369-3373. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Ther. Patents (2001) 11(4)
   Google Scholar
• CHENG SY, HUANG HJ, NAGANE M et al: Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc. Natl. Acad. Sci. USA (1996) 93:8502–8507.
   PubMed Web of Science ®Google Scholar
• HUA XY, CHEN P, POLGAR E et al: Spinal neurokinin NK1 receptor down-regulation and antinociception: effects of spinal NK1 receptor antisense oligonucleo-tides and NK1 receptor occupancy. J. Neurochem. (1998) 70:688–698.
   PubMed Web of Science ®Google Scholar
• GARRY MG, MALIK S, YU J, DAVIS MA, YANG J: Knock down of spinal NNIDA receptors reduces NNIDA and formalin evoked behaviors in rat. NeuroReport (2000) 11:49–55.
   PubMedGoogle Scholar
• WIESENFELD-HALLIN Z, LUCAS GA, ALSTER P, XU X-J, HOKFELT T: Cholecystokinin/opioid interactions. Brain Res. (1999) 848:78–89.
   PubMed Web of Science ®Google Scholar
• TANG NM, DONG HVV, WANG XM, TSUI ZC, HAN JS: Cholecystokinin antisense RNA increases the analgesic effect induced by electroacupuncture or low dose morphine: conversion of low responder rats into high responders. Pain (1997) 71:71–80.
   PubMedGoogle Scholar
• ABEL MS, KOHLI N: GABA-transaminase antisense oligodeoxynucleotide modulates cocaine- and pen tylenetetrazol-in duced seizures in mice. Metab. Brain Dis. (1999) 14:253–263.
   PubMedGoogle Scholar
• KATSUMORI H, HASHIMOTO K, TOMITAKA S, OSAWA M, MINABE Y: Acute effect of c-fos antisense oligode-oxynucleotide on hipp ocamp al partial seizures elicited by electrical stimulation in rats. Neurosci. Lett. (1997) 225:149–152.
   PubMedGoogle Scholar
• HEBB MO, ROBERTSON HA: End-capped antisense oligodeoxynucleotides effectively inhibit gene expres-sion in vivo and offer a low-toxicity alternative to fully modified phosphorothioate oligodeoxynucleotides. Mol Brain Res. (1997) 47:223–228.
   PubMedGoogle Scholar
• AKHTAR S, HUGHES MD, KHAN A et al.: The delivery of antisense therapeutics. Adv. Drug Deily. Reviews (2000) 44:3–21.
   PubMed Web of Science ®Google Scholar
• BOADO RJ, TSUKAMOTO H, PARDRIDGE WM: Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS. J. Pharmaceut. Sci. (1998) 87:1308–1315.
   PubMed Web of Science ®Google Scholar
• SHI N, PARDRIDGE WM: Noninvasive gene targeting to the brain. Proc. Natl. Acad. Sci. USA (2000) 97:7567–7572.
   PubMed Web of Science ®Google Scholar
• STUART DD, ALLEN TM: A new liposomal formulation for antisense oligonucleotides with small size, high incorporation efficiency and good stability. Biochim. Biophys. Acta - Biomembranes (2000) 1463:219–229.
   PubMed Web of Science ®Google Scholar
• PHYLACTOU LA, LEE MB, WOOD MJA: Ribozymes: oligonucleotides with enzymatic activity have potential as regulators of gene expression in the CNS. In: Antisense Technology in the Central Nervous System. Leslie RA, Hunter AJ, Robertson HA (Eds.): Oxford Univer-sity Press, Oxford, UK (1999):218–229.
   Google Scholar
• LARSEN HJ, BENTIN T, NIELSEN PE: Antisense properties of peptide nucleic acid. Bloch. Biophys. Acta - Gene Structure and Expression (1999) 1489:159–166.
   PubMed Web of Science ®Google Scholar
• WAHLESTEDT C, SALMI P, GOOD L et al.: Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc. Natl. Acad. Sci. USA (2000) 97:5633–5638.
   PubMed Web of Science ®Google Scholar
• TAVITIAN B, TERRAZZINO S, KUHNAST B et al.: In vivo imaging of oligonucleotides with positron emission tomography. Nat. Med. (1998) 4:467–471.
   PubMed Web of Science ®Google Scholar
• KOBORI N, IMAHORI Y, MINEURA K, UEDA S, FUJII R: Visualization of mRNA expression in CNS using 11C-labeled phosphorothioate oligodeoxynucleotide. NeuroReport (1999) 10:2971–2974.
   PubMedGoogle Scholar
• WU F, YNGVE U, HEDBERG E et al.: Distribution of Br-76-labeled antisense oligonucleotides of different length determined ex vivo in rats. Eur. J. Pharmaceut. Sci. (2000) 10:179–186.
   PubMed Web of Science ®Google Scholar